TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma

By afschroeder • May 17, 2026

Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming M, Klauss G, Lin D, Liu C, Apolo AB, Powles T. TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. Future Oncol. 2026 May 16:1-10. doi: 10.1080/14796694.2026.2663956. Epub ahead of print. PMID: 42142358.

Tags: Antibody–drug conjugate (ADC), Bladder cancer, datopotamab deruxtecan (Dato-DXd), Hematology/Oncology, locally advanced, metastatic, platinum-based chemotherapy, Publications, Trophoblast cell surface antigen 2 (TROP2), urothelial carcinoma

Related Posts

BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma

Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer[...]

A compendium of next-generation patient-derived models for diverse cancers

ElHarouni D, Al-Jazrawe M, Choi S, Dede M, Hinoue T, Misek SA, Noh H, Zanella L, Tseng YY, Francies HE, Plenker D, Kyi CW, Perez-Mayoral[...]

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]